Equities

KeyMed Biosciences Inc

KeyMed Biosciences Inc

Actions
  • Price (HKD)38.70
  • Today's Change0.85 / 2.25%
  • Shares traded1.30m
  • 1 Year change-23.97%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,7193,1753,525
Total Receivables, Net807.4414
Total Inventory564416
Prepaid expenses818024
Other current assets, total3.412.252.94
Total current assets2,9403,3103,582
Property, plant & equipment, net911596306
Goodwill, net------
Intangibles, net1.111.501.10
Long term investments222120
Note receivable - long term0.071.2722
Other long term assets5.522.542.19
Total assets3,8833,9323,934
LIABILITIES
Accounts payable29152.78
Accrued expenses1109150
Notes payable/short-term debt000
Current portion long-term debt/capital leases657212
Other current liabilities, total10920248
Total current liabilities314380112
Total long term debt3535027
Total debt41912239
Deferred income tax0.28----
Minority interest0.50(1.07)(5.59)
Other liabilities, total228164150
Total liabilities897592283
SHAREHOLDERS EQUITY
Common stock0.170.170.17
Additional paid-in capital8,4848,4858,516
Retained earnings (accumulated deficit)(5498)(5145)(4865)
Treasury stock - common0.000.00--
Unrealized gain (loss)------
Other equity, total------
Total equity2,9863,3403,651
Total liabilities & shareholders' equity3,8833,9323,934
Total common shares outstanding280277280
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.